BMS-986205 + nivolumab + ipilimumab

BMS-986205 + nivolumab + ipilimumab is an investigational combination immunotherapy regimen composed of three components: - **BMS-986205**: a potent and selective small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme involved in immune suppression in the tumor microenvironment. - **Nivolumab**: a monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity. - **Ipilimumab**: a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), also a checkpoint inhibitor aimed at enhancing T-cell mediated immune response. This triple combination is being investigated for the treatment of advanced and metastatic cancers, with the aim of overcoming tumor immunosuppression and increasing anti-tumor efficacy through simultaneous inhibition of IDO1 and both PD-1 and CTLA-4 checkpoints. Studies focus on patients with advanced or metastatic solid tumors, including bladder cancer, hepatocellular carcinoma, melanoma, and others[2][5]. The combination seeks to leverage potential synergy between IDO1 inhibition and dual checkpoint blockade to enhance anti-tumor immune activity[2][7].

Other names

BMS-986205 + Opdivo + Yervoy